sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_7 ;
    pav:version "20131211" .
  sub:_6 prov:value "Treatment of human umbilical vein endothelial cells (HUVEC) with vascular endothelial growth factor (VEGF, 25 ng/ml) promoted tyrosine phosphorylation and activation of KDR which associates with PLC-gamma and phosphorylates at tyrosine residue. This effect was inhibited by SU5416, a specific KDR antagonist. It was also shown that either (N or C-terminal) SH2 may mediate interaction with tyrosine 951 in KDR; tyrosine 1175 also fosters KDR/PLC-gamma interaction. Treatment with PlGF (Flt1 agonist) had no effect, suggesting that VEGF induces activation of PLC-gamma is mediated via KDR receptor." ;
    prov:wasQuotedFrom pubmed:10671553 .
  sub:_7 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:10671553 ;
    prov:wasDerivedFrom beldoc: , sub:_6 .
}